Research progress of the medicine treatment of advanced lung squamous cell carcinoma
10.3760/cma.j.issn.1006-9801.2016.05.021
- VernacularTitle:晚期肺鳞状细胞癌内科治疗研究进展
- Author:
Xiaoxue LIU
- Publication Type:Journal Article
- Keywords:
Lung neoplasms;
Carcinoma,squamous cell;
Drug therapy;
Molecular targeted therapy;
Immune checkpoint inhibitors
- From:
Cancer Research and Clinic
2016;28(5):357-360
- CountryChina
- Language:Chinese
-
Abstract:
In the last decade,many molecular targeted drugs,such as epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI),have been successively applied in clinical use,and they have brought about a substantial prolongation of survival life and improvement in life quality of those patients with lung adenocarcinoma,but that is not real in squamous cell lung cancer.Immunotherapy clinical trials for programmed death receptor-1 (PD-1)/programmed death ligand-1 (PD-L1) pathway in non-small cell lung cancer (NSCLC) have been started since 2012.In 2015,an anti-PD-1 antibody,nivolumab,was proved by FDA to treat advanced squamous NSCLC with progression on or after platinum-based chemotherapy.This article reviews the recent advantages in the treatment of advanced lung squamous cell carcinoma.
